Species differences in blood-brain barrier transport of three positron emission tomography radioligands with emphasis on P-glycoprotein transport

Drug Metabolism and Disposition

Volumn 37, Issue 3, 2009, Pages 635-643

  Syvänen, Stina ^a,b,d   Lindhe, Örjan ^b   Palner, Mikael ^c   Kornum, Birgitte R ^c   Rahman, Obaidur ^b   Långström, Bengt ^a,b   Knudsen, Gitte M ^c   Hammarlund Udenaes, Margareta ^a  

^a UPPSALA UNIVERSITY   (Sweden)

^b BIACORE AB   (Sweden)

^c Mental Health Services CPH   (Denmark)

^d LEIDEN UNIVERSITY   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ALTANSERIN; CYCLOSPORIN A; GLYCOPROTEIN P; VERAPAMIL; VOFOPITANT;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BLOOD BRAIN BARRIER; CONTINUOUS INFUSION; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG BRAIN LEVEL; DRUG PENETRATION; DRUG PROTEIN BINDING; FEMALE; GUINEA PIG; HUMAN; ISOTOPE LABELING; LIGAND BINDING; MINIPIG; MONKEY; MOUSE; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RADIOCHEMISTRY; RAT; SPECIES DIFFERENCE; TRANSPORT KINETICS;

ANIMALS; BLOOD PROTEINS; BLOOD-BRAIN BARRIER; GUINEA PIGS; HUMANS; MACACA FASCICULARIS; P-GLYCOPROTEIN; POSITRON-EMISSION TOMOGRAPHY; PROTEIN BINDING; PROTEIN TRANSPORT; RADIOLIGAND ASSAY; RATS; SPECIES SPECIFICITY;

CAVIA; RATTUS; RODENTIA;

EID: 61449118888     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.108.024745     Document Type: Article

References (47)

1. Baltes S, Gastens AM, Fedrowitz M, Potschka H, Kaever V, and Löscher W (2007) Differences in the transport of the antiepileptic drugs phenytoin, levetiracetam and carbamazepine by human and mouse P-glycoprotein. Neuropharmacology 52:333-346.
2. Bart J, Dijkers EC, Wegman TD, de Vries EG, van der Graaf WT, Groen HJ, Vaalburg W, Willemsen AT, and Hendrikse NH (2005) New positron emission tomography tracer [(11)C]carvedilol reveals P-glycoprotein modulation kinetics. Br J Pharmacol 145:1045-1051.
3. 11C]verapamil measured with PET. Neuroimage 20:1775-1782.
4. 1-antagonists, GR203040 and GR205171-PET studies in rhesus monkey. Neuropharmacology 39:664-670.
5. 2 receptors in humans using positron emission tomography. Eur J Nucl Med 21:937-946.
6. Cserr HF and Bundgaard M (1984) Blood-brain interfaces in vertebrates: a comparative approach. Am J Physiol 246:R277-R288.
7. Cutler L, Howes C, Deeks NJ, Buck TL, and Jeffrey P (2006) Development of a P-glycoprotein knockout model in rodents to define species differences in its functional effect at the blood-brain barrier. J Pharm Sci 95:1944-1953.
8. 11C-GR218231 as PET tracer for P-glycoprotein. J Nucl Med 46:1384-1392.
9. Doze P, Van Waarde A, Elsinga PH, Hendrikse NH, and Vaalburg W (2000) Enhanced cerebral uptake of receptor ligands by modulation of P-glycoprotein function in the blood-brain barrier. Synapse 36:66-74.
10. Elfving B, Bjørnholm B, and Knudsen GM (2003) Interference of anaesthetics with radioligand binding in neuroreceptor studies. Eur J Nucl Med Mol Imaging 30:912-915.
11. Furmark T, Appel L, Michelgård A, Wahlstedt K, Ahs F, Zancan S, Jacobsson E, Flyckt K, Grohp M, Bergström M, et al. (2005) Cerebral blood flow changes after treatment of social phobia with the neurokinin-1 antagonist GR205171, Citalopram, or placebo. Biol Psychiatry 58:132-142.
12. Haneda E, Higuchi M, Maeda J, Inaji M, Okauchi T, Ando K, Obayashi S, Nagai Y, Narazaki M, Ikehira H, et al. (2007) In vivo mapping of substance P receptors in brains of laboratory animals by high-resolution imaging systems. Synapse 61:205-215.
13. Harada N, Ohba H, Fukumoto D, Kakiuchi T, and Tsukada H (2004) Potential of [(18)F]betaCFT-FE (2beta-carbomethoxy-3beta-(4-fluorophenyl)-8-(2-[(18)F] fluoroethyl)nortropane) as a dopamine transporter ligand: a PET study in the conscious monkey brain. Synapse 54:37-45.
14. Hendrikse NH, de Vries EG, Eriks-Fluks L, van der Graaf WT, Hospers GA, Willemsen AT, Vaalburg W, and Franssen EJ (1999) A new in vivo method to study P-glycoprotein transport in tumors and the blood-brain barrier. Cancer Res 59:2411-2416.
15. Henthorn TK, Liu Y, Mahapatro M, and Ng KY (1999) Active transport of fentanyl by the blood-brain barrier. J Pharmacol Exp Ther 289:1084-1089.
16. Hsiao P, Sasongko L, Link JM, Mankoff DA, Muzi M, Colher AC, and Unadkat JD (2006) Verapamil P-glycoprotein transport across the rat blood-brain barrier: cyclosporine, a concentration inhibition analysis, and comparison with human data. J Pharmacol Exp Ther 317:704-710.
17. Hubbard TJ, Aken BL, Beal K, Ballester B, Caccamo M, Chen Y, Clarke L, Coates G, Cunningham F, Cutts T, et al. (2007) Ensembl 2007. Nucleic Acids Res 35:D610-D617.
18. Katoh M, Suzuyama N, Takeuchi T, Yoshitomi S, Asahi S, and Yokoi T (2006) Kinetic analyses for species differences in P-glycoprotein-mediated drug transport. J Pharm Sci 95:2673-2683.
19. Lacán G, Plenevaux A, Rubins DJ, Way BM, Defraiteur C, Lemaire C, Aerts J, Luxen A, Cherry SR, and Melega WP (2008) Cyclosporine, a P-glycoprotein modulator, increases [(18)F]MPPF uptake in rat brain and peripheral tissues: microPET and ex vivo studies. Eur J Nucl Med Mol Imaging 5:5.
20. Lazarova N, Zoghbi SS, Hong J, Seneca N, Tuan E, Gladding RL, Liow JS, Taku A, Innis RB, and Pike VW (2008) Synthesis and evaluation of [N-methyl-11C]N-desmethyl-loperamide as a new and improved PET radiotracer for imaging P-gp function. J Med Chem 51:6034-6043.
21. 11C]verapamil. J Pharmacol Exp Ther 316:647-653.
22. Lemaire C, Cantineau R, Guillaume M, Plenevaux A, and Christiaens L (1991) Fluorine-18-altanserin: a radioligand for the study of serotonin receptors with PET: radiolabeling and in vivo biologic behavior in rats. J Nucl Med 32:2266-2272.
23. 11C](R)-(-)-RWAY. Synapse 61:96-105.
24. Liptrot M, Adams KH, Martiny L, Pinborg LH, Lonsdale MN, Olsen NV, Holm S, Svarer C, and Knudsen GM (2004) Cluster analysis in kinetic modelling of the brain: a noninvasive alternative to arterial sampling. Neuroimage 21:483-493.
25. 11C]verapamil as PET tracer of P-glycoprotein function in the blood-brain barrier: kinetics and metabolism in the rat. Nucl Med Biol 32:87-93.
26. Michelgård A, Appel L, Pissiota A, Frans O, Långström B, Bergström M, and Fredrikson M (2007) Symptom provocation in specific phobia affects the substance P neurokinin-1 receptor system. Biol Psychiatry 61:1002-1006.
27. Ohe T, Sato M, Tanaka S, Fujino N, Hata M, Shibata Y, Kanatani A, Fukami T, Yamazaki M, Chiba M, et al. (2003) Effect of P-glycoprotein-mediated efflux on cerebrospinal fluid/plasma concentration ratio. Drug Metab Dispos 31:1251-1254.
28. 18F]MPPF in rats. Eur J Pharmacol 407:273-280.
29. 18F]MPPF. J Nucl Med 41:1830-1835.
30. 18F]altanserin-PET and the bolus/infusion approach. J Cereb Blood Flow Metab 23:985-996.
31. 1 receptor) antagonists SR140333 and GR205171: a comparative study using mdrla-/- and mdrla+/+ mice. Behav Pharmacol 14:457-463.
32. Sasongko L, Link JM, Muzi M, Mankoff DA, Yang X, Collier AC, Shoner SC, and Unadkat JD (2005) Imaging P-glycoprotein transport activity at the human blood-brain barrier with positron emission tomography. Clin Pharmacol Ther 77:503-514.
33. Staley JK, Van Dyck CH, Tan PZ, Al Tikriti M, Ramsby Q, Klump H, Ng C, Garg P, Soufer R, Baldwin RM, et al. (2001) Comparison of [(18)F]altanserin and [(18)F]deuteroaltanserin for PET imaging of serotonin(2A) receptors in baboon brain: pharmacological studies. Nucl Med Biol 28:271-279.
34. Suzuyama N, Katoh M, Takeuchi T, Yoshitomi S, Higuchi T, Asashi S, and Yokoi T (2007) Species differences of inhibitory effects on P-glycoprotein- mediated drug transport. J Pharm Sci 96:1609-1618.
35. Syvänen S (2003) Evaluation of plasma-to-brain PK-models for an NK1-receptor antagonist based on positron emission tomography investigations. Master's thesis, Uppsala University, Uppsala, Sweden.
36. Syvänen S, Blomquist G, Sprycha M, Höglund AU, Roman M, Eriksson O, Hammarlund-Udenaes M, Långström B, and Bergström M (2006) Duration and degree of cyclosporin induced P-glycoprotein inhibition in the rat blood-brain barrier can be studied with PET. Neuroimage 32:1134-1141.
37. 11C]propyl iodide and initial PET-imaging. BMC Med Imaging 7:6.
38. Syvänen S, Hooker A, Rahman O, Wilking H, Blomquist G, Långstrom B, Bergström M, and Hammarlund-Udenaes M (2008) Pharmacokinetics of P-glycoprotein inhibition in the rat blood-brain barrier. J Pharm Sci 97:5386-5400.
39. 18F]altanserin in human and rodent. Nucl Med Biol 26:601-608.
40. Tatusova TA and Madden TL (1999) BLAST 2 Sequences, a new tool for comparing protein and nucleotide sequences. FEMS Microbiol Lett 174:247-250.
41. Tsukada H, Nishiyama S, Kakiuchi T, Ohba H, Sato K, Harada N, and Nakanishi S (1999) Isoflurane anesthesia enhances the inhibitory effects of cocaine and GBR12909 on dopamine transporter: PET studies in combination with microdialysis in the monkey brain. Brain Res 849:85-96.
42. Watanabe H, Andersen F, Simonsen CZ, Evans SM, Gjedde A, and Cumming P (2001) MR-based statistical atlas of the Gottingen minipig brain. Neuroimage 14:1089-1096.
43. Xia CQ, Xiao G, Liu N, Pimprale S, Fox L, Patten CJ, Crespi CL, Miwa G, and Gan LS (2006) Comparison of species differences of P-glycoproteins in beagle dog, rhesus monkey, and human using Atpase activity assays. Mol Pharm 3:78-86.
44. Yamazaki M, Neway WE, Ohe T, Chen I, Rowe JF, Hochman JH, Chiba M, and Lin JH (2001) In vitro substrate identification studies for p-glycoprotein- mediated transport: species difference and predictability of in vivo results. J Pharmacol Exp Ther 296:723-735.
45. 11C](R)-(-)-RWAY. Synapse 60:510-520.
46. 11C](R)-(-)-RWAY: radiometabolite(s) likely confound brain measurements. Synapse 61:469-477.
47. Zoghbi SS, Liow JS, Yasuno F, Hong J, Tuan E, Lazarova N, Gladding RL, Pike VW, and Innis RB (2008) HC-Loperamide and its N-desmethyl radiometabolite are avid substrates for brain permeability-glycoprotein efflux. J Nucl Med 49:649-656.